SEC Form 4 · accession 0001628280-26-046653

Contineum Therapeutics, Inc. · CTNM

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CEO and President · Director

Period of report

Jun 30, 2026

Accepted (ET)

Jul 1, 2026 · 7:04 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001855175

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Class A Common Stock	Jun 30, 2026	M	7,500	$1.01	A	24,717	D
Class A Common Stock	Jun 30, 2026	M	2,500	$1.26	A	27,217	D
Class A Common Stock^F2,F3	Jun 30, 2026	S	10,000	$16.008	D	17,217	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F4	$1.01	Jun 30, 2026	M	7,500	D	—	Feb 24, 2030	Class A Common Stock	7,500	281,930	D
Stock Option (right to buy)^F4	$1.26	Jun 30, 2026	M	2,500	D	—	Nov 13, 2028	Class A Common Stock	2,500	118,417	D

F1These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.12, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3Includes 5,605 shares of the Issuer's Class A Common Stock acquired by the Reporting Person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c).
F4Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.